Edgardo Bermudez Moreno, MD
Cardiovascular Disease · Ponce, PRNPI 1891746624
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,674 of the $17,954 with a category attached, or 81.7%. 20 manufacturers reported payments, led by Abbott at 27.0% of the total. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$5K
- Medtronic$3K
- Edwards Lifesciences$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Johnson & Johnson$1K
- plus $2K from 14 others
What the payments were for
- Travel & lodging$3,20518%
- Food & beverage$14,67482%
- Gifts$750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $4,844 |
| Boston Scientific | 163 | $4,781 |
| Medtronic(2 entities) | 91 | $2,831 |
| Edwards Lifesciences | 56 | $1,533 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 69 | $1,057 |
| Johnson & Johnson | 42 | $1,038 |
| PBG Puerto Rico LLC | 24 | $429 |
| AstraZeneca | 15 | $389 |
| Boehringer Ingelheim | 15 | $341 |
| Amgen | 10 | $207 |
| Chiesi USA, Inc. | 3 | $112 |
| E.r. Squibb & Sons, L.L.C. | 4 | $101 |
| Cordis US CORP. | 4 | $66 |
| Teleflex LLC | 2 | $62 |
| Cardinal Health P.r. 120 Inc | 4 | $50 |
| Bayer Puerto Rico Inc. | 1 | $27 |
| Merck | 1 | $25 |
| Biotronik Inc. | 1 | $24 |
| Bayer | 1 | $21 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$2,124
- OPTIS$1,075
- CoreValve Evolut$260
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$203
- SYMPLICITY G3$161
- CROSSBOSS$158
- STINGRAY$150
- GENERAL VASCULAR ACCESS$150
- XIENCE SIERRA$135
- WATCHMAN FLX$127
- FARXIGA$125
- ONYX FRONTIER$125
- MAMBA$122
- GENERAL - THERAPIES$120
- LUX-Dx Insertable Cardiac Monitor$117
- Edwards SAPIEN 3 Transcatheter Heart Valve$100
- INVOKANA$100
- AVEIR$100
How this compares
$17,954 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $270,945 |
| EliquisApixaban | 394 | $247,893 |
| JardianceEmpagliflozin | 273 | $182,187 |
| BrilintaTicagrelor | 294 | $146,539 |
| FarxigaDapagliflozin Propanediol | 202 | $126,336 |
| XareltoRivaroxaban | 93 | $57,217 |
| EntrestoSacubitril/Valsartan | 44 | $30,304 |
| Metoprolol Succinate | 1,774 | $19,219 |
| Losartan Potassium | 1,588 | $12,153 |
| Nifedipine ErNifedipine | 766 | $11,982 |
| Ranolazine ErRanolazine | 246 | $11,166 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 896 | $9,128 |
| ClopidogrelClopidogrel Bisulfate | 956 | $7,632 |
| Atorvastatin Calcium | 992 | $7,475 |
| Candesartan Cilexetil | 117 | $6,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $389 | $272,875496 claims |
| Boehringer IngelheimJardiance | $341 | $182,187273 claims |
| Johnson & JohnsonXarelto | $1,038 | $57,21793 claims |
| NovartisEntresto | $16 | $30,30444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Ponce
- Ulises Rodriguez RamosPonce$44K
- Edwin MolinaPonce$40K
- Vanessa Rodriguez MierPonce$14K
- Brian Gonzalez SanabiaPonce$10K
- Jose GomezPonce$8K
- Oscar Quintero-SerranoPonce$7K
- Gerardo Alayon AntaPonce$7K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.